Regeneron Pharmaceuticals (REGN)
$706.94
16.53 (2.28%)
REGN Stock Quote Delayed 30 Minutes
Poor Quant Score Limit Regeneron Pharmaceuticals (REGN) Rating
Currently, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has a Hold using the methodology for investing of Louis Navellier and his Portfolio Grader stock evaluator. REGN has maintained this ranking for 5 months.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
64.88B
PE Ratio
18.44
EPS
38.33
Volume (Avg. Vol.)
713,051
Day's Range
$701.07 - $721.41
52-Week Range
$642.00 - $1,211.20
Dividend & Yield
N/A (N/A)
REGN Stock Predictions, Articles, and Regeneron Pharmaceuticals News
Rating on Regeneron Pharmaceuticals (REGN) Upgraded to Buy From a Hold
The current recommendation of Buy for Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is computed using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. REGN has been upgraded from a Hold to a Buy in the last week.
3 Big Stock Charts for Thursday: Tripadvisor Inc (TRIP), Regeneron Pharmaceuticals Inc (REGN) and Lam Research Corporation (LRCX)
Tripadvisor (TRIP), Lam Research (LRCX) and Regeneron REGN) all made one-day moves that confirmed that higher prices are likely over the next 2-3 months.
Regeneron Pharmaceuticals Inc (REGN) Stock Looks Good Despite the Backdrop
Piper Jaffrey analyst Ed Tenthoff called REGN stock a buy today, seeing the bigger Regeneron Pharmaceuticals story that's about to unfold.
5 Stocks with Solid Sales Growth Catching Eyeballs (REGN, RJF, DG, XEL, MS)
Sales growth is an important indicator of a company's health and ability to sustain its business and these 5 stocks to buy are great examples
The SPDR S&P Biotech (ETF) (XBI) Is on Breakout Watch
Biotech stocks are quietly climbing higher. Here's how to trade the SPDR S&P Biotech (ETF) (XBI) before its seemingly imminent pop.
The 10 Highest-Paid CEOs for 2016
A study has been released that details the highest-paid CEOs in the U.S. for 2016 and Charter Communications' Tom Rutledge tops the list.
Go Long Regeneron Pharmaceuticals Inc (REGN) Stock at a Discount
Regeneron is up, and it's probably not wise to chase REGN stock right now, but there are safer ways to play it.
Is Now the Time to Buy Into These 5 Biotech ETFs?
After a painful 2016, biotech stocks are recovering this year. What lies ahead? Let's look at 5 biotech ETFs to find out
Amgen, Inc. (AMGN) Q4 Earnings Preview
Amgen (AMGN) reports Q4 earnings on Thursday, and if something does weigh on AMGN stock, it'll likely be one of these three factors.
